Melanie Miller, MD
Family Medicine · Trussville, ALNPI 1053480574
Payments from drug & device makers
Across 298 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$779
- Lilly USA, LLC$416
- AstraZeneca$415
- Novo Nordisk$414
- Takeda Pharmaceuticals U.S.A., Inc.$258
- IBSA Pharma Inc.$222
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,281100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 92 | $779 |
| Lilly USA, LLC | 27 | $416 |
| AstraZeneca | 23 | $415 |
| Novo Nordisk | 25 | $414 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $258 |
| IBSA Pharma Inc. | 12 | $222 |
| Merck | 12 | $213 |
| Pfizer | 11 | $189 |
| Exact Sciences | 9 | $165 |
| Boehringer Ingelheim | 7 | $146 |
| Biohaven Pharmaceuticals, Inc. | 10 | $138 |
| Abbott | 8 | $130 |
| Acella Pharmaceuticals, LLC | 7 | $127 |
| Amgen | 6 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $76 |
| GSK | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Astellas Pharma US Inc | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $37 |
| Esperion Therapeutics, Inc. | 3 | $35 |
| Amarin Pharma, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Azurity Pharmaceuticals, Inc. | 2 | $29 |
| Dexcom, Inc. | 1 | $24 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
| Bayer | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$4,287 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $95,167 |
| JardianceEmpagliflozin | 45 | $50,170 |
| MounjaroTirzepatide | 36 | $37,154 |
| EliquisApixaban | 38 | $35,879 |
| FarxigaDapagliflozin Propanediol | 25 | $26,458 |
| JanuviaSitagliptin Phosphate | 15 | $19,250 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $18,913 |
| XareltoRivaroxaban | 20 | $15,721 |
| Liothyronine Sodium | 172 | $15,366 |
| RybelsusSemaglutide | 13 | $12,276 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,864 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $10,671 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,834 |
| Bupropion XlBupropion Hcl | 40 | $5,799 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $414 | $107,443108 claims |
| Boehringer IngelheimJardiance | $146 | $50,17045 claims |
| Lilly USA, LLCMounjaro | $416 | $37,15436 claims |
| PfizerEliquis | $189 | $35,87938 claims |
| AstraZenecaFarxiga | $415 | $26,45825 claims |
| MerckJanuvia | $213 | $19,25015 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $53 | $18,91323 claims |
| Johnson & JohnsonXarelto | $37 | $15,72120 claims |
| GSKBreo Ellipta | $57 | $7,83420 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $258 | $5,04011 claims |
| AbbVieArmour Thyroid | $779 | $3,85044 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $127 | $2,70936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Trussville
- Andrew SmithTrussville$17K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.